Alectinib shows promise in phase 3 ALINA trial for non-small cell lung cancer By Investing.com
© Reuters.
The 2023 ESMO Congress showcased the results of the phase 3 ALINA trial, revealing that alectinib, an oral ALK inhibitor, significantly improved disease-free survival (DFS) in patients with resected stage IB-IIIA…
